FDA-cleared profile

AI-Rad Companion Brain MR

Siemens Healthcare GmbH · MRI · FDA-cleared (510(k))

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Clinical role
Segmentation, quantitative post-processing and follow-up comparison
Images and patients
MRI · Brain
Key limitation
Keep in mind: Quantitative post-processing assists clinician evaluation. WMH follow-up permits changes in field strength, pixel spacing and slice thickness in VA60; a field-strength difference produces an information message.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: T1 MPRAGE for brain morphometry. The VA60 comparison table specifies T2-weighted 3D FLAIR alone for WMH, with WMH follow-up at 1.5 T and 3 T and Siemens, GE and Philips inputs.
  • Who uses it?Intended users: Healthcare professionals familiar with post-processing magnetic resonance images.
  • What does the software produce?Output: Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.
  • What is its most important limitation?Key limitation: Quantitative post-processing assists clinician evaluation. WMH follow-up permits changes in field strength, pixel spacing and slice thickness in VA60; a field-strength difference produces an information message.

Clinical takeaway. Clinical role: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Evidence takeaway. Evidence from the reviewed source record: VA60 WMH testing used 100 subjects and follow-up testing used 165 subjects, with manually annotated reference data. Morphometry and morphometry follow-up were unchanged from the predicate. Testing supports the modified quantitative features, not a new prospective outcome benefit.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Segmentation, quantitative post-processing and follow-up comparison
  • Exact FDA submission
  • Checked 2026-09-05
Required input
T1 MPRAGE for brain morphometry. The VA60 comparison table specifies T2-weighted 3D FLAIR alone for WMH, with WMH follow-up at 1.5 T and 3 T and Siemens, GE and Philips inputs.
  • Exact FDA submission
  • Checked 2026-09-06

The specific VA60 input-data row streamlines the predecessor T1-plus-FLAIR requirement, although introductory prose still repeats the older combination. Do not use the older VA51 manual as the VA60 acquisition specification.

Output and clinician action
Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Baseline population label retained; it is not a claim that all modules have identical age restrictions.

Intended users
Healthcare professionals familiar with post-processing magnetic resonance images.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Quantitative post-processing assists clinician evaluation. WMH follow-up permits changes in field strength, pixel spacing and slice thickness in VA60; a field-strength difference produces an information message.
  • Exact FDA submission
  • Checked 2026-09-05

This does not establish unrestricted mixing of acquisitions or that normative values from different software tools are interchangeable.

Evidence summary
VA60 WMH testing used 100 subjects and follow-up testing used 165 subjects, with manually annotated reference data. Morphometry and morphometry follow-up were unchanged from the predicate. Testing supports the modified quantitative features, not a new prospective outcome benefit.
  • Exact FDA submission
  • Checked 2026-09-06

Preserves the baseline 100-subject cohort and adds the separately described 165-subject follow-up cohort; these are not pooled as unique patients.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
VA60 WMH testing used 100 subjects and follow-up testing used 165 subjects, with manually annotated reference data. Morphometry and morphometry follow-up were unchanged from the predicate. Testing supports the modified quantitative features, not a new prospective outcome benefit.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06

Preserves the baseline 100-subject cohort and adds the separately described 165-subject follow-up cohort; these are not pooled as unique patients.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

No product-wide VA60 clinical sensitivity is promoted. Segmentation/follow-up endpoints and an older tool-to-tool volumetry study are not interchangeable with diagnosis.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

No product-wide VA60 clinical specificity is established by the reviewed evidence.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K253057 WMH segmentation validation

  • DesignStandalone evaluation against manually annotated ground truth from three radiologists
  • Population100 subjects including multiple sclerosis, Alzheimer disease, cognitive impairment and healthy controls; 1.5 T/3 T Siemens, GE and Philips MRI
  • Scopeexact submission
  • Tested versionAI-Rad Companion Brain MR VA60 WMH feature
  • Samplen=100
  • IndependenceSponsor or vendor study

K253057

K253057 WMH follow-up validation

  • DesignStandalone new/enlarged WMH evaluation against annotated longitudinal reference data
  • Population165 subjects with multiple sclerosis or Alzheimer disease scanned at 1.5 T/3 T on Siemens, GE and Philips systems
  • Scopeexact submission
  • Tested versionAI-Rad Companion Brain MR VA60 WMH follow-up
  • Samplen=165
  • IndependenceSponsor or vendor study

K253057

Validity Assessment of an Automated Brain Morphometry Tool for Patients with De Novo Memory Symptoms

  • DesignRetrospective comparison with FreeSurfer 7.1.1/Individual Longitudinal Participant processing and clinical impressions
  • PopulationT1-weighted MRI from 45 OASIS-4 participants with de novo memory symptoms
  • Scopeproduct family
  • Tested versionAI-Rad Companion Brain MR; no VA60 linkage in reviewed abstract
  • Samplen=45
  • IndependenceIndependence not established

PMID:36797031 · DOI:10.3174/ajnr.A7790

Strong correlation did not imply agreement of absolute volumes or standardized values across tools. No VA60 diagnostic sensitivity/specificity is inferred. Full-text disclosure review remains incomplete.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

Downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: T1 MPRAGE for brain morphometry. The VA60 comparison table specifies T2-weighted 3D FLAIR alone for WMH, with WMH follow-up at 1.5 T and 3 T and Siemens, GE and Philips inputs.

    Scope: Exact FDA submission. The specific VA60 input-data row streamlines the predecessor T1-plus-FLAIR requirement, although introductory prose still repeats the older combination. Do not use the older VA51 manual as the VA60 acquisition specification.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · AI-Rad Companion Brain MR VA60: K253057 clearance and summary

  2. Routing

    Source context, not route validation: Generated maps and reports can be exported to PACS; the summary describes confirmation and configuration UI components.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · AI-Rad Companion Brain MR VA60: K253057 clearance and summary

  3. AI processing

    Source context, not route validation: Cloud solution and edge components on customer premises.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · AI-Rad Companion Brain MR VA60: K253057 clearance and summary

  4. Returned objects

    Source context, not route validation: Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · AI-Rad Companion Brain MR VA60: K253057 clearance and summary

  5. Viewer/worklist/report

    Unresolved route: Absolute and normalized brain-structure volumes, age-matched normative comparisons and deviation/label maps; WMH count and volume in four brain regions, maps of new or enlarged WMH on follow-up, and numeric/visual reports sent to PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · AI-Rad Companion Brain MR VA60: K253057 clearance and summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud solution and edge components on customer premises.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
Generated maps and reports can be exported to PACS; the summary describes confirmation and configuration UI components.
  • Exact FDA submission
  • Checked 2026-09-06
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Monitoring
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.

PACS output

Maps and numeric/visual reports can be exported to PACS.

exact submission · checked 2026-09-06

Predecessor review workflow

VA51 vendor data sheet describes browser confirm/reject, automatic PACS routing and optional processing-status notifier; current VA60 configuration requires confirmation.

product family · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253057
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
21Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored metadata screened September 5. Primary author-institution abstract reviewed September 6 after PubMed/PMC verification barriers; retained as 45-participant family volumetry study, not VA60 results. Stored trial array was empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor technical documentation, peer reviewed literature, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    VA60 module, cloud/edge infrastructure, PACS integration and service prices are not established from reviewed materials.

  • Pricing model: Not verified - checked 2026-09-06 - Exact FDA submission

    Per-case, module and enterprise terms require a version-specific quote.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Siemens Healthineers AI-Rad Companion reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-06 - Exact FDA submission

    A predecessor data sheet is available, but exact VA60 onboarding, competency and support terms were not verified.

9 sources - 3 history items

Source ledger

  1. AI-Rad Companion Brain MR VA60: K253057 clearance and summary

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: purpose, clinicalUse, modality, anatomy, input, output, limitations, deployment, integration, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AI-Rad Companion Brain MR model card (K253057)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AI-Rad Companion Brain MR VA51 data sheet, valid January 2025

    Siemens Healthineers Academy - Accessed 2026-09-06

    Scope: productFamilyContext, implementationCapabilities

  8. Validity Assessment of an Automated Brain Morphometry Tool for Patients with De Novo Memory Symptoms

    American Journal of Neuroradiology / Washington University Research Profiles - Accessed 2026-09-06

    Scope: evidenceStudies, productFamilyContext

  9. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K253057 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22
FDA-cleared K251483

SwiftSight-Brain

AIRS Medical Inc.

Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.

Modality
MRI
Anatomy
Brain
Decision
2025-09-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history